OCUGEN, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
OCUGEN, INC. (OCGN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$356.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- OCUGEN, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $5.04M, a 141.94% increase year-over-year.
- OCUGEN, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$5.40M.
- OCUGEN, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.21M, a 42.27% decline year-over-year.
- OCUGEN, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $3.29M, a 52.20% increase year-over-year.
- OCUGEN, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $3.31M, a 19.97% decline from fiscal 2024.
- OCUGEN, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $4.14M.
- OCUGEN, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$12.34M, a 230.10% decline from fiscal 2022.
- OCUGEN, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $9.49M, a 171.21% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$356.00K 10-Q · filed 2026-08-06 | $850.00K derived: sum of 3 quarters · filed 2026-08-06 | $4.14M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$5.40M 10-Q · filed 2026-05-08 | -$4.19M derived: sum of 2 quarters · filed 2026-05-08 | -$903.00K derived: sum of 3 quarters · filed 2026-05-08 | $1.18M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $4.50M derived: sum of 2 quarters · filed 2026-03-04 | $6.58M derived: sum of 3 quarters · filed 2026-08-06 | $3.31M 10-K · filed 2026-03-04 | ||||
| 2025-09-30 | $3.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.37M derived: sum of 2 quarters · filed 2026-08-06 | $2.10M 10-Q · filed 2025-11-05 | $4.19M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.18M 10-Q · filed 2026-08-06 | $905.00K derived: sum of 3 quarters · filed 2026-08-06 | $3.07M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$3.27M 10-Q · filed 2026-05-08 | -$1.18M derived: sum of 2 quarters · filed 2026-05-08 | $982.00K derived: sum of 3 quarters · filed 2026-05-08 | $2.31M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $4.25M derived: sum of 2 quarters · filed 2026-03-04 | $5.58M derived: sum of 3 quarters · filed 2026-03-04 | $4.14M 10-K · filed 2026-03-04 | ||||
| 2024-09-30 | $2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.49M derived: sum of 2 quarters · filed 2025-11-05 | $2.05M 10-Q · filed 2025-11-05 | $107.00K derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$113.00K 10-Q · filed 2025-08-04 | -$2.05M derived: sum of 3 quarters · filed 2025-08-04 | -$3.41M derived: sum of 4 quarters · filed 2025-08-04 | ||||
| 2024-03-31 | -$1.45M 10-Q · filed 2025-05-09 | -$3.39M derived: sum of 2 quarters · filed 2025-05-09 | -$4.74M derived: sum of 3 quarters · filed 2025-05-09 | -$8.82M derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$3.29M derived: sum of 2 quarters · filed 2025-03-05 | -$7.38M derived: sum of 3 quarters · filed 2025-03-05 | -$12.34M 10-K · filed 2025-03-05 | ||||
| 2023-09-30 | -$1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$5.44M derived: sum of 2 quarters · filed 2024-11-14 | -$10.40M 10-Q · filed 2024-11-14 | -$10.06M 10-Q · filed 2023-11-09 | -$7.65M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | -$4.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$9.05M 10-Q · filed 2024-08-08 | -$8.63M 10-Q · filed 2023-08-21 | -$6.30M derived: sum of 3 quarters · filed 2024-08-08 | -$2.41M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | -$4.96M 10-Q · filed 2024-05-14 | -$4.78M 10-Q · filed 2023-05-05 | -$2.21M derived: sum of 2 quarters · filed 2024-05-14 | $1.68M derived: sum of 3 quarters · filed 2024-05-14 | $4.39M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $2.75M derived: 10-K 12 month − 10-K 9 month · filed 2024-04-16 | $6.64M derived: sum of 2 quarters · filed 2024-04-16 | $9.36M derived: sum of 3 quarters · filed 2024-04-16 | $9.49M 10-K · filed 2024-04-16 | ||||
| 2022-09-30 | $3.89M derived: 10-K 9 month − 10-K 6 month · filed 2024-04-16 | $6.60M derived: sum of 2 quarters · filed 2024-04-16 | $6.73M 10-K · filed 2024-04-16 | $6.59M 10-Q · filed 2022-11-08 | $7.31M derived: sum of 4 quarters · filed 2024-04-16 | |||
| 2022-06-30 | $2.71M derived: 10-K 6 month − 10-K 3 month · filed 2024-04-16 | $2.84M 10-K · filed 2024-04-16 | $3.42M derived: sum of 3 quarters · filed 2024-04-16 | $4.86M derived: sum of 4 quarters · filed 2024-04-16 | ||||
| 2022-03-31 | $131.00K 10-K · filed 2024-04-16 | $704.00K derived: sum of 2 quarters · filed 2024-04-16 | $2.15M derived: sum of 3 quarters · filed 2024-04-16 | $3.22M derived: sum of 4 quarters · filed 2024-04-16 | ||||
| 2021-12-31 | $573.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.02M derived: sum of 2 quarters · filed 2023-02-28 | $3.09M derived: sum of 3 quarters · filed 2023-02-28 | $3.50M 10-K · filed 2023-02-28 | ||||
| 2021-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.52M derived: sum of 2 quarters · filed 2022-11-08 | $2.92M 10-Q · filed 2022-11-08 | $3.52M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $1.48M 10-Q · filed 2022-08-05 | $2.08M derived: sum of 3 quarters · filed 2022-08-05 | $2.16M derived: sum of 4 quarters · filed 2022-08-05 | ||||
| 2021-03-31 | $405.00K 10-Q · filed 2022-05-06 | $997.00K derived: sum of 2 quarters · filed 2022-05-06 | $1.08M derived: sum of 3 quarters · filed 2022-05-06 | $1.09M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $592.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $679.00K derived: sum of 2 quarters · filed 2022-02-28 | $684.00K derived: sum of 3 quarters · filed 2022-02-28 | -$541.00K 10-K · filed 2022-02-28 | -$540.85K 10-K · filed 2021-03-19 | |||
| 2020-09-30 | $87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $92.00K derived: sum of 2 quarters · filed 2021-11-09 | -$1.13M 10-Q · filed 2021-11-09 | -$1.13M 10-Q · filed 2020-11-06 | -$4.81M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$1.22M 10-Q · filed 2021-08-06 | -$1.22M 10-Q · filed 2020-08-14 | -$4.89M derived: sum of 3 quarters · filed 2022-02-28 | -$3.50M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | -$1.23M 10-Q · filed 2021-05-07 | -$1.23M 10-Q · filed 2020-05-08 | -$4.90M derived: sum of 2 quarters · filed 2022-02-28 | -$3.51M derived: sum of 3 quarters · filed 2022-02-28 | -$4.58M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | -$3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$2.28M derived: sum of 2 quarters · filed 2022-02-28 | -$3.35M derived: sum of 3 quarters · filed 2022-02-28 | -$1.63M 10-K · filed 2022-02-28 | -$1.63M 10-K · filed 2020-03-27 | |||
| 2019-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $321.39K derived: sum of 2 quarters · filed 2020-11-06 | $2.04M 10-Q · filed 2020-11-06 | $2.05M 10-Q · filed 2019-11-12 | $4.26M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2019-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $653.77K 10-Q · filed 2020-08-14 | $668.88K 8-K/A · filed 2019-10-07 | $2.87M derived: sum of 3 quarters · filed 2020-08-14 | $2.53M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | $1.72M 10-Q · filed 2020-05-08 | $3.94M derived: sum of 2 quarters · filed 2020-05-08 | $3.60M derived: sum of 3 quarters · filed 2020-05-08 | |||||
| 2018-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $1.87M derived: sum of 2 quarters · filed 2020-03-27 | $3.63M 10-K · filed 2020-03-27 | |||||
| 2018-09-30 | -$346.33K derived: 10-Q 9 month − 8-K/A 6 month · filed 2019-11-12 | $1.41M 10-Q · filed 2019-11-12 | ||||||
| 2018-06-30 | $1.76M 8-K/A · filed 2019-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |